MI Profile
Use
MI Profile comprehensive profiling assesses DNA, RNA, and proteins from tumor tissue to provide a complete molecular blueprint. This helps guide precise and individualized treatment decisions by revealing crucial molecular insights. It is suitable for profiling therapy options and understanding molecular characteristics of tumors, enhancing the precision of personalized treatment plans for cancer patients.
Special Instructions
Includes next-generation sequencing (NGS), immunohistochemistry (IHC), chromogenic in situ hybridization (CISH), pyrosequencing, and AI-predictive algorithms. Some tests may reflex to alternate assays if specimen requirements are not met. AI signatures like Caris GPSai® and FOLFIRSTai® are applicable for specific cases.
Limitations
The MI Profile test is limited to the detection of actionable biomarkers and may not identify all genetic alterations. For samples not meeting the specific specimen criteria, certain tests may not be performed. The presence of mutations and biomarkers, though detected, requires clinical correlation for accurate therapy decisions. Consulting accompanying sample guidelines is necessary for optimal results.
New York Approved
Methodology
NGS (Whole Exome)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
1 unstained slide at 4μm thickness from FFPE block
Collection Instructions
Ensure evaluable tumor is present on the FFPE block slide.
Causes for Rejection
Slides without sufficient tumor cells, improper fixation, or degraded samples.
Other tests from different labs that may be relevant